-
The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
Spencer K, Bindra R, Cacho AM, Nicolaides KH.
Prenat Diagn 2004;24:169-73. -
Prediction of fetal anemia in rhesus disease by measurement of fetal middle cerebral artery peak systolic velocity.
Scheier M, Hernandez-Andrade E, Carmo A, Dezerega V, Nicolaides KH.
Ultrasound Obstet Gynecol 2004;23:432-6. -
The role of uterine artery Doppler in predicting adverse pregnancy outcome.
Papageorghiou AT, Yu CK, Nicolaides KH.
Best Pract Res Clin Obstet Gynaecol 2004;18:383-96. -
Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities.
Nicolaides KH.
Am J Obstet Gynecol 2004;191:45-67. -
Fetal middle cerebral artery peak systolic velocity in the investigation of non-immune hydrops.
Hernandez-Andrade E, Scheier M, Dezerega V, Carmo A, Nicolaides KH.
Ultrasound Obstet Gynecol 2004;23:442-5. -
Predicting the severity of fetal anemia using time-domain measurement of volume flow in the fetal aorta.
Harrington K, Fayyad A, Nicolaides KH.
Ultrasound Obstet Gynecol 2004;23:437-41. -
Glycosaminoglycans and proteoglycans in the skin of aneuploid fetuses with increased nuchal translucency.
von Kaisenberg CS, Prols F, Nicolaides KH, Maass N, Meinhold-Heerlein I, Brand-Saberi B.
Hum Reprod 2003;18:2544-61. -
Delta-NT or NT MoM: which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester?
Spencer K, Bindra R, Nix AB, Heath V, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;22:142-8. -
Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience.
Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH.
BJOG 2003;110:281-6. -
Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia.
Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH.
Lancet 2003;361:1511-7. -
Sonographic markers of fetal aneuploidy: a review.
Cicero S, Sacchini C, Rembouskos G, Nicolaides KH.
Placenta 2003;24:S88-98. -
Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
Cicero S, Bindra R, Rembouskos G, Spencer K, Nicolaides KH.
Prenat Diagn 2003;23:306-10. -
Absent nasal bone at 11-14 weeks of gestation and chromosomal defects.
Cicero S, Longo D, Rembouskos G, Sacchini C, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;22:31-5. -
Comparison of color Doppler uterine artery indices in a population at high risk for adverse outcome at 24 weeks' gestation.
Albaiges G, Missfelder-Lobos H, Parra M, Lees C, Cooper D, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;21:170-3. -
The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues.
Wilting J, Papoutsi M, Christ B, Nicolaides KH, von Kaisenberg CS, Borges J, Stark GB, Alitalo K, Tomarev SI, Niemeyer C, Rossler J.
FASEB J 2002;16:1271-3. -
A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A.
Spencer K, Nicolaides KH.
Prenat Diagn 2002;22:877-9. -
Congenital nephrotic syndrome presenting with increased nuchal translucency in the first trimester.
Souka AP, Skentou H, Geerts L, Bower S, Nicolaides KH.
Prenat Diagn 2002;22:93-5. -
Congenital lymphedema presenting with increased nuchal translucency at 13 weeks of gestation.
Souka AP, Krampl E, Geerts L, Nicolaides KH.
Prenat Diagn 2002;22:91-2. -
Hypophosphatasia associated with increased nuchal translucency: a report of two affected pregnancies.
Souka AP, Raymond FL, Mornet E, Geerts L, Nicolaides KH.
Ultrasound Obstet Gynecol 2002;20:294-5. -
Blackfan-Diamond anemia and dyserythropoietic anemia presenting with increased nuchal translucency at 12 weeks of gestation.
Souka AP, Bower S, Geerts L, Huggon I, Nicolaides KH.
Ultrasound Obstet Gynecol 2002;20:197-9.